Please Wait
Applying Filters...
menu
    • menu
    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-08-25

    Virtual Booth

    An Enquiry

    Menu

    Namodenoson

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Can-Fite's Namodenoson Hits 50% Enrollment in Phase 2a Study
    Can-Fite's Namodenoson Hits 50% Enrollment in Phase 2a Study

    30 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/30/3123927/0/en/Pancreatic-Cancer-Phase-2a-Study-with-Can-Fite-s-Namodenoson-Achieved-Over-50-Enrollment-Milestone.html

    GLOBENEWSWIRE
    30 Jul 2025
    Share Share
    U.S. Medical Centers Seek Authorization for Namodenoson
    U.S. Medical Centers Seek Authorization for Namodenoson

    17 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/17/3063424/0/en/Following-FDA-Compassionate-Use-Approval-for-Pancreatic-Carcinoma-with-Can-Fite-s-Namodenoson-Leading-U-S-Medical-Centers-Seek-Authorization-for-their-Patients.html

    GLOBENEWSWIRE
    17 Apr 2025
    Share Share
    Can-Fite: FDA Approves Use of Namodenoson in Pancreatic Cancer
    Can-Fite: FDA Approves Use of Namodenoson in Pancreatic Cancer

    18 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/03/18/3044514/0/en/Can-Fite-FDA-Approved-Compassionate-Use-Treatment-with-Namodenoson-in-a-Pancreatic-Cancer-Patient.html

    GLOBENEWSWIRE
    18 Mar 2025
    Share Share
    Can-Fite Publishes Namodenoson Benefits In Liver Cancer
    Can-Fite Publishes Namodenoson Benefits In Liver Cancer

    03 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/03/03/3035375/0/en/Can-Fite-Innovative-Publication-Namodenoson-in-Liver-Cancer-Treatment-Alongside-with-Cardiac-Liver-and-Neurological-Benefits.html

    GLOBENEWSWIRE
    03 Mar 2025
    Share Share
    Can-Fite’s Namodenoson Clears Decompensated Liver Cirrhosis
    Can-Fite’s Namodenoson Clears Decompensated Liver Cirrhosis

    18 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/18/3027671/0/en/Disappearance-of-Decompensated-Liver-Cirrhosis-Episodes-After-Treatment-with-Can-Fite-s-Namodenoson.html

    GLOBENEWSWIRE
    18 Feb 2025
    Share Share
    ASCO Recognizes Can-Fite’s Namodenoson Liver Protective Effect
    ASCO Recognizes Can-Fite’s Namodenoson Liver Protective Effect

    30 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/30/3002592/0/en/Recognition-of-the-American-Society-of-Clinical-Oncology-ASCO-of-the-Liver-Protective-Effect-of-Can-Fite-s-anti-Cancer-Drug-Namodenoson.html

    GLOBENEWSWIRE
    30 Dec 2024
    Share Share